Literature DB >> 25681086

Analysis of HGD Gene Mutations in Patients with Alkaptonuria from the United Kingdom: Identification of Novel Mutations.

Jeannette L Usher1, David B Ascher2, Douglas E V Pires2, Anna M Milan3, Tom L Blundell2, Lakshminarayan R Ranganath3.   

Abstract

Alkaptonuria (AKU) is a rare autosomal recessive disorder with incidence ranging from 1:100,000 to 1:250,000. The disorder is caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase (HGD), which results from defects in the HGD gene. This enzyme converts homogentisic acid to maleylacetoacetate and has a major role in the catabolism of phenylalanine and tyrosine. To elucidate the mutation spectrum of the HGD gene in patients with alkaptonuria from 42 patients attending the National Alkaptonuria Centre, 14 exons of the HGD gene and the intron-exon boundaries were analysed by PCR-based sequencing. A total of 34 sequence variants was observed, confirming the genetic heterogeneity of AKU. Of these mutations, 26 were missense substitutions and four splice site mutations. There were two deletions and one duplication giving rise to frame shifts and one substitution abolishing the translation termination codon (no stop). Nine of the mutations were previously unreported novel variants. Using computational approaches based on the 3D structure, these novel mutations are predicted to affect the activity of the protein complex through destabilisation of the individual protomer structure or through disruption of protomer-protomer interactions.

Entities:  

Keywords:  Alkaptonuria; Homogentisic acid; Novel mutation; Rare genetic disorder; Sequencing

Year:  2015        PMID: 25681086      PMCID: PMC4582018          DOI: 10.1007/8904_2014_380

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  26 in total

1.  The nature of the defect in tyrosine metabolism in alcaptonuria.

Authors:  B N LA DU; V G ZANNONI; L LASTER; J E SEEGMILLER
Journal:  J Biol Chem       Date:  1958-01       Impact factor: 5.157

2.  Ab initio prediction of mutation-induced cryptic splice-site activation and exon skipping.

Authors:  Petr Divina; Andrea Kvitkovicova; Emanuele Buratti; Igor Vorechovsky
Journal:  Eur J Hum Genet       Date:  2009-01-14       Impact factor: 4.246

3.  Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.

Authors:  A T Hughes; A M Milan; P Christensen; G Ross; A S Davison; J A Gallagher; J J Dutton; L R Ranganath
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-06-07       Impact factor: 3.205

4.  Identification of 11 Novel Homogentisate 1,2 Dioxygenase Variants in Alkaptonuria Patients and Establishment of a Novel LOVD-Based HGD Mutation Database.

Authors:  Andrea Zatkova; Tatiana Sedlackova; Jan Radvansky; Helena Polakova; Martina Nemethova; Robert Aquaron; Ismail Dursun; Jeannette L Usher; Ludevit Kadasi
Journal:  JIMD Rep       Date:  2011-10-20

5.  The molecular basis of alkaptonuria.

Authors:  J M Fernández-Cañón; B Granadino; D Beltrán-Valero de Bernabé; M Renedo; E Fernández-Ruiz; M A Peñalva; S Rodríguez de Córdoba
Journal:  Nat Genet       Date:  1996-09       Impact factor: 38.330

6.  Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition.

Authors:  A M Taylor; A J Preston; N K Paulk; H Sutherland; C M Keenan; P J M Wilson; B Wlodarski; M Grompe; L R Ranganath; J A Gallagher; J C Jarvis
Journal:  Osteoarthritis Cartilage       Date:  2012-04-24       Impact factor: 6.576

7.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

Review 8.  Alkaptonuria in Slovakia: thirty-two years of research on phenotype and genotype.

Authors:  Stefan Srsen; Clemens R Müller; Andreas Fregin; Klara Srsnova
Journal:  Mol Genet Metab       Date:  2002-04       Impact factor: 4.797

9.  SNAP: predict effect of non-synonymous polymorphisms on function.

Authors:  Yana Bromberg; Burkhard Rost
Journal:  Nucleic Acids Res       Date:  2007-05-25       Impact factor: 16.971

10.  mCSM: predicting the effects of mutations in proteins using graph-based signatures.

Authors:  Douglas E V Pires; David B Ascher; Tom L Blundell
Journal:  Bioinformatics       Date:  2013-11-26       Impact factor: 6.937

View more
  24 in total

1.  Progress in Alkaptonuria--are we near to an effective therapy?

Authors:  L R Ranganath; O G Timmis; J A Gallagher
Journal:  J Inherit Metab Dis       Date:  2015-09       Impact factor: 4.982

2.  Prediction of impacts of mutations on protein structure and interactions: SDM, a statistical approach, and mCSM, using machine learning.

Authors:  Arun Prasad Pandurangan; Tom L Blundell
Journal:  Protein Sci       Date:  2019-11-25       Impact factor: 6.725

3.  A Founder Effect for the HGD G360R Mutation in Italy: Implications for a Regional Screening of Alkaptonuria.

Authors:  Berardino Porfirio; Roberta Sestini; Greta Gorelli; Miriam Cordovana; Alessandro Mannoni; Jeanette L Usher; Wendy J Introne; William A Gahl; Thierry Vilboux
Journal:  JIMD Rep       Date:  2016-03-10

4.  mmCSM-AB: guiding rational antibody engineering through multiple point mutations.

Authors:  Yoochan Myung; Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2020-07-02       Impact factor: 16.971

5.  SDM: a server for predicting effects of mutations on protein stability.

Authors:  Arun Prasad Pandurangan; Bernardo Ochoa-Montaño; David B Ascher; Tom L Blundell
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

6.  mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures.

Authors:  Douglas E V Pires; David B Ascher
Journal:  Nucleic Acids Res       Date:  2016-05-23       Impact factor: 16.971

7.  Variant Analysis of Alkaptonuria Families with Significant Founder Effect in Jordan.

Authors:  Raida Khalil; Dema Ali; Nesrin Mwafi; Arwa Alsaraireh; Loiy Obeidat; Eman Albsoul; Ibrahim Al Sbou'
Journal:  Biomed Res Int       Date:  2021-03-11       Impact factor: 3.411

8.  Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.

Authors:  Jody Phelan; Francesc Coll; Ruth McNerney; David B Ascher; Douglas E V Pires; Nick Furnham; Nele Coeck; Grant A Hill-Cawthorne; Mridul B Nair; Kim Mallard; Andrew Ramsay; Susana Campino; Martin L Hibberd; Arnab Pain; Leen Rigouts; Taane G Clark
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

9.  Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.

Authors:  Ana Carolina Rios Silvino; Gabriel Luiz Costa; Flávia Carolina Faustino de Araújo; David Benjamin Ascher; Douglas Eduardo Valente Pires; Cor Jesus Fernandes Fontes; Luzia Helena Carvalho; Cristiana Ferreira Alves de Brito; Tais Nobrega Sousa
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity.

Authors:  Douglas E V Pires; Jing Chen; Tom L Blundell; David B Ascher
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.